|
|
|
|
||
Re: Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafInteresting lesson in biotech trading. AdComm recommended approval 14:1. Anyone familiar with inpatient medicine knows the difficulty of treating candida and the need for a better drug. EVERYONE knew it would be approved. So when approval actually happened there were no new buyers. |
return to message board, top of board |